Opiant Pharmaceuticals, Inc. Common Stock
OPNT
OPNT was delisted on the 1st of March, 2023.
14 hedge funds and large institutions have $2.16M invested in Opiant Pharmaceuticals, Inc. Common Stock in 2018 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 4
4% less capital invested
Capital invested by funds: $2.25M → $2.16M (-$85.9K)
13% less funds holding
Funds holding: 16 → 14 (-2)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.54M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$56.3K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$54.9K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
+$12.5K |
| 5 |
RA
Royce & Associates
New York
|
+$2.27K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VCM
Venator Capital Management
Toronto,
Ontario, Canada
|
-$774K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$238K |
| 3 |
SIM
Spark Investment Management
New York
|
-$225K |
| 4 |
Morgan Stanley
New York
|
-$68.7K |
| 5 |
TCM
Tradewinds Capital Management
Bellingham,
Washington
|
-$57K |
OPNT Hedge Fund Activity: Q1 2018 in Review
14 of the 4,364 institutional investors tracked by Wall St. Rank reported a position in Opiant Pharmaceuticals, Inc. Common Stock (OPNT) for Q1 2018, worth a combined $2.16M — down 3.8% from $2.25M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of OPNT and 3 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 4 added.
The largest buyer was Vanguard Group, adding an estimated $1.54M. The largest seller was Venator Capital Management, exiting entirely with an estimated $774K sold.
- 14 institutional investors held Opiant Pharmaceuticals, Inc. Common Stock (OPNT) as of Q1 2018, down from 16 in Q4 2017.
- Funds reported $2.16M of Opiant Pharmaceuticals, Inc. Common Stock stock for Q1 2018, down 3.8% quarter-over-quarter.
- 3 funds opened new Opiant Pharmaceuticals, Inc. Common Stock positions in Q1 2018 and 5 closed out, a net change of -2 holders.
- The largest Opiant Pharmaceuticals, Inc. Common Stock buyer in Q1 2018 was Vanguard Group, an estimated $1.54M added.
- The largest Opiant Pharmaceuticals, Inc. Common Stock seller in Q1 2018 was Venator Capital Management, an estimated $774K sold.
Based on aggregated 13F filings for Q1 2018.